通过适当的抗高血压疗法获得极大的可持续性
Francesco Ferrara1, Andrea Zovi2, Eduardo Nava3
1Pharmaceutical Department, Hospital Pharmacist Manager, ASL Napoli 3 Sud, Naples, Italy.
Current problems in cardiology
|June 10, 2023
概括
这项研究分析了意大利抗高血压药物的处方趋势,突出了ACE抑制剂和利尿剂等药物类别之间的成本和疗效差异. 了解这些差异是有效控制心血管疾病的关键.
科学领域:
- 心脏病学 心脏病学
- 药物经济学 药物经济学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病是全球死亡和住院的主要原因.
- 许多抗高血压药物类别,包括ACE抑制剂,沙坦,抗体,β阻断剂和利尿剂,被广泛使用.
- 这些药物的疗效,耐受性和成本存在显著差异.
研究的目的:
- 分析抗高血压药物的处方趋势.
- 检查这些疗法的药物经济和药物利用方面.
- 描述抗高血压药物类别之间的药理学差异.
主要方法:
- 对处方数据的回顾性分析.
- 专注于欧洲医疗保健环境 (意大利公司,约100万居民).
- 对药物类别的利用,成本和药理学概况的评估.
主要成果:
- 确定了各种抗高血压药物类别的不同处方模式.
- 在药物类别内和药物类别之间,每月治疗费用的显著差异.
- 药物机制的突出变化,降低血压的有效性和耐受性.
结论:
- 抗高血压药物的处方趋势受到药理学,经济和利用因素的影响.
- 在不同类型的抗高血压药物中,成本效益和治疗效果有很大差异.
- 需要进一步分析以优化基于个体患者需求和经济考虑的抗高血压治疗选择.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
19
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
19
Hypertension V: Nursing Management
13
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
13
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15


